PLASMA COMPOSITIONS AND METHODS OF USE THEREOF
Provided herein are pathogen-inactivated plasma compositions and methods for treating a disease or condition using pathogen-inactivated plasma compositions.
1 . A method of treating a disease or condition indicated for treatment by plasma exchange in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of pathogen-inactivated plasma composition by plasma exchange, wherein the pathogen-inactivated plasma composition comprises pathogen-inactivated cryo-poor plasma.
2 . The method of claim 1 , wherein the disease or condition is indicated for treatment with albumin by plasma exchange.
3 . The method of claim 1 , wherein the disease or condition is other than thrombocytopenic purpura (TTP) or hemolytic-uremic syndrome (HUS).
4 - 5 . (canceled)
6 . The method of claim 1 , wherein the disease or condition is thrombocytopenic purpura (TTP) or hemolytic-uremic syndrome (HUS).
7 - 10 . (canceled)
11 . The method of claim 1 , wherein the pathogen-inactivated plasma composition is administered within 5 days after thawing.
12 . The method of claim 1 , wherein the pathogen-inactivated plasma composition is a lyophilized or freeze-dried plasma composition.
13 - 66 . (canceled)
67 . The method of claim 1 , wherein the plasma exchange is achieved with a volume of the plasma composition between about 1 times and about 1.5 times the subject's plasma volume.
68 . The method of claim 1 , wherein the plasma exchange is achieved with a volume of the plasma composition comprising about 30 mL/kg, about 40 mL/kg, about 50 mL/kg, or about 60 mL/kg patient body weight.
69 . The method of claim 1 , wherein the plasma exchange is performed at least two times.
70 . The method of claim 69 , wherein the plasma exchange is performed 2-5 times.
71 . The method of claim 69 , wherein the plasma exchange is performed 2-5 times within a period of two weeks.
72 . The method of claim 1 , wherein the pathogen-inactivated plasma composition comprises pathogen-inactivated cryo-poor plasma prepared from one or more units of plasma from whole blood donation.
73 . The method of claim 1 , wherein the pathogen-inactivated plasma composition comprises pathogen-inactivated cryo-poor plasma prepared from one or more plasma units from apheresis collected plasma.
74 . The method of claim 1 , wherein the pathogen-inactivated plasma composition comprises pathogen-inactivated cryo-poor plasma prepared from one or more units of plasma that are subjected to pathogen inactivation within 24 hours of donation.
75 . The method of claim 1 , wherein the pathogen-inactivated plasma composition comprises pathogen-inactivated cryo-poor plasma prepared from multiple plasma units.
76 . The method of claim 1 , wherein the pathogen-inactivated cryo-poor plasma is prepared from plasma that is pathogen-inactivated by photochemical inactivation.
77 . The method of claim 1 , wherein the pathogen-inactivated cryo-poor plasma is prepared from plasma that is pathogen-inactivated with a psoralen.